Abstract
To implement pharmacokinetic drug monitoring and individualize the posology of new antiepileptic drugs, the first HPLC-diode array detection method was developed and validated to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. Preceded by a reproducible liquid-liquid extraction, chromatographic separation was achieved by using a C18 column of 5cm length and a mobile phase of water/acetonitrile. Full validation was performed according to international guidelines. The method was linear within 0.5-30, 2.5-40.0 and 0.5-50.0μg ml-1 for lacosamide, levetiracetam and zonisamide, respectively (r2 ≥ 0.998), accurate (-12.411-8.303%), precise (≤8.875%). This innovative HPLC-diode array detection method was successfully employed in clinical practice and is expected to empower epileptic patients with a personalized pharmacotherapy service. [Formula: see text].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
